Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

Kyle LaHucik

Senior Reporter

Stealth BioTherapeutics’ lead drug has failed a Phase II study in an eye disease, dealing another blow to the biotech’s elamipretide as the treatment had …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Stealth's lead drug flunks again, this time in an eye dis­ease, but biotech will at­tempt to push for­ward

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials